2022. A Review of the Risk of Cutaneous Squamous Cell Carcinoma after Vismodegib Therapy. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), 453–457. DOI:https://doi.org/10.25251/skin.6.6.1.